The tests look for bits of altered DNA that cancer cells shed into the bloodstream. The screening technology holds hope of ...

GRAIL’s Galleri test shows promise in early cancer detection, but regulatory delays and valuation concerns temper enthusiasm. Find out why GRAL stock is a hold.

CHICAGO -- Hundreds of people using the test company Grail were wrongly told they might have cancer, the company said in a statement Monday. Grail said a software glitch related to their telemedicine ...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings from the PATHFINDER study of ...

Grail (NASDAQ:GRAL) announced Wednesday that its Galleri test led to improved cancer detection when added to standard-of-care cancer screening in its PATHFINDER 2 registrational trial. Citing topline ...

MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with ...

For doctors and patients, the Holy Grail of medicine would be a simple blood or saliva test to detect all types of cancer before symptoms or sickness appears. Doctors could ...

GRAIL Inc. (NASDAQ:GRAL) is one of the best young stocks to buy and hold for 5 years. On June 18, GRAIL announced positive top-line performance and safety results from the pre-specified analysis of ...

For doctors and patients, the Holy Grail of medicine would be a simple blood or saliva test to detect all types of cancer ...

CEO Robert P. Ragusa reported continued strong commercial momentum, highlighting that "Galleri test orders continue to grow at a strong clip with more than 45,000 Galleri commercial tests sold in the ...